Hepatitis B Seroprotection and the Response to a Challenging Dose among Vaccinated Children in Red Sea Governorate


  • Samia M. Sami National Research Center, Child Health, Cairo
  • Iman I. Salama National Research Center, Community Medicine Research, Cairo
  • Ghada A. Abdel-Latif National Research Center, Community Medicine Research, Cairo
  • Lobna A. El Etreby National Research Center, Community Medicine Research, Cairo
  • Ahmed I. Metwally National Research Center, Community Medicine Research, Cairo
  • Naglaa F. Abd El haliem Faculty of Medicine, Al Azhar University - Microbiology and Immunology, Cairo




Anamnestic response, Booster dose, Seroprotection, HBV vaccine, Children, Egypt


AIM: To assess the long-term effectiveness of hepatitis B virus vaccine and the need for a booster dose among children who received three doses of vaccine during infancy in Red Sea Governorate.

METHODS: A cross-sectional study was performed. Interviews with children (9 months to 16 years) and parents were done. Blood samples to assess Hepatitis B markers were tested. Children showing no seroprotection received a booster dose to assess their anamnestic response after four weeks and one year later.

RESULTS: None of the participants had evidence of chronic Hepatitis B. The seroprotection rate was 23.3% and it significantly decreased with age. Multivariate logistic analysis revealed that older age was the significant predicting variable for having no seroprotective level, while baseline anti-HBs level < 3.3 IU/L was the predicting variable for not developing early anamnestic response or loss of late anamnestic response.

CONCLUSION: Long-term immunity persists among children who received complete series of hepatitis B vaccination during infancy even in absence or reduction of anti-HBs over time. Therefore, a booster dose is not necessary to maintain immunity till the age of sixteen.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Huang C, Dai C, Chuang W, Ho C, Wu T, Hou N, Wang C, Hsieh M, Huang J, Lin Z, Chen S, Hsieh M, Wang L, Tsai J, Chang W, Yu M. HBV infection in indigenous children, 20 years after immunization in Taiwan: A community-based study. Elsevier Inc. Preventive Medicine. 2009;48:397–400. http://dx.doi.org/10.1016/j.ypmed.2009.02.002 PMid:19463479

World Health Organization (WHO). Hepatitis B.1. Geneva, (WHO Fact sheet, No. 204. (http://www.who.int/mediacentre/factsheets/fs204/en/index.html, accessed 18 May 2009).

Talaat M, El-Sayed N, Kandeel A, Azab MA, Afifi S, Youssef FG, Ismael T, Hajjeh R, Mahoney FJ. Sentinel surveillance for patients with acute hepatitis in Egypt, 2001–04. Eastern Mediterranean Health Journal (EMHJ). 2010;16(2).

Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B Virus Infection: Epidemiology and Vaccination. From the Epidemiology Branch, Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Accepted for publication March 28, 2006.

Han K, Shao X, Zheng H, Wu C, Zhu J, Zheng X, Zhang Y. Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule. Human Vaccines & Immunotherapeutics. 2012;8:12,1845–1849. http://dx.doi.org/10.4161/hv.21818 PMid:22906933 PMCid:PMC3656074

Chen D. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. Journal of Hepatology. 2009; 50:805–816. http://dx.doi.org/10.1016/j.jhep.2009.01.002 PMid:19231008

Eldesoky A, Mosaad Y, Zakria Y, Hamdy S. Protective immunity after hepatitis B vaccination. 2009; 10(2):68–71.

van der Sande MAB, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey SJ, Jeffries D, Hall AJ, Whittle HC. Long-Term Protection against Carriage of Hepatitis B Virus after Infant Vaccination. The Journal of Infectious Diseases. 2007; 193:1528–35. http://dx.doi.org/10.1086/503433 PMid:16652281

Zhu C, Liu P, Chen T, Ni Z, Lu L, Huang F, Lu J, Sun Z, Qu C. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine. 2011;29:7835–7841. http://dx.doi.org/10.1016/j.vaccine.2011.07.098 PMid:21816197

Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, Bell BP. Differences in Response to a Hepatitis B Vaccine Booster Dose Among Alaskan Children and Adolescents Vaccinated During Infancy. Pediatrics. 2007;120(2): e373-e381. http://dx.doi.org/10.1542/peds.2007-0131 PMid:17636112

Jimenez AP, Sharaf El-Din N, El-Hoseiny M, El-Daly M, Abdel-Hamid M, El Aidi S, Sultan Y, El- Sayed N, Mohamed MK, Fontanet A. Community transmission of hepatitis B virus in Egypt: results from a case–control study in Greater Cairo. International Journal of Epidemiology. 2009;38:757–765. http://dx.doi.org/10.1093/ije/dyp194 PMid:19420088

Youssef A, Yano Y, ZakiM E, Utsumi T, Hayashi Y. Characteristics of hepatitis viruses among Egyptian children with acute hepatitis. 2013: 1459-1465.

Fahmy SI, El-Sherbiny AF. Determining simple parameters for social classifications for health research. The Bulletin of the High institute of Public Health. 1983;18(5):95-103.

World Health Organization (WHO). Hepatitis B. WHO/CDS/CSR/mLYO/. 2002;2:1–76.

Zanetti A, Parlato A, Romanò L, Desole MG, Ferrera G, Giurdanella F et al. Challenge with a hepatitis B vaccine in two cohorts of 4-7-year-old children primed with hexavalent vaccines: an open-label,randomised trial in Italy. Vaccine. 2012; 30(39): 5770-5. http://dx.doi.org/10.1016/j.vaccine.2012.06.078 PMid:22789511

Shouval D. Hepatitis B vaccines. Journal of Hepatology. 2003;39:S70-76. http://dx.doi.org/10.1016/S0168-8278(03)00152-1

Burgessa MA, McIntyrea PB, Hellardb M, Ruffc TA, Lefevred I, Bockd HL. Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine. 2010;28:2222–2226. http://dx.doi.org/10.1016/j.vaccine.2009.12.053 PMid:20056187

Mendy M, Peterson I, Hossin S, Peto T, Jobarteh ML, Jeng-Barry A, Sidibeh M, Jatta A, Moore SE, Hall AJ, Whittle H. Observational Study of Vaccine Efficacy 24 Years after the Start of Hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One. 2013; 8(3):e58029. http://dx.doi.org/10.1371/journal.pone.0058029 PMid:23533578 PMCid:PMC3606345

Banatvala J. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000;355:561–65. http://dx.doi.org/10.1016/S0140-6736(99)07239-6

Salama II, Sami SM, Salama SI, Foud WA, Abdel Hamid AT, Said ZN. Persistence of protection to hepatitis B vaccine and response to booster dose among children and adolescents in Dakahleya- Egypt. Egyptian Journal of Immunology, 2014;21 (1): 13-26. PMid:25204041

Aypak C, Yüce A, Yıkılkan H, Görpelioğlu S. Persistence of protection of hepatitis B vaccine and response to booster immunization in 2- to 12-year-old children. Eur J Pediatr. 2012;171:1761–1766. http://dx.doi.org/10.1007/s00431-012-1815-4 PMid:22895894

Zanetti AR, Mariano A, Roman L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, Parlato A, Zamparo E, Zotti C, Stroffolini T, Mele A, and the Study Group. Long- term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005;366: 1379–84. http://dx.doi.org/10.1016/S0140-6736(05)67568-X

Hassan S, Ziba F. Antibody titre in Iranian children 6 years after hepatitis B vaccine administration. Vaccine. 2007; 25 (17):3511-4. http://dx.doi.org/10.1016/j.vaccine.2005.09.037 PMid:17400337

Yazdanpanah B, Safari M, Yazdanpanah S. Persistence of HBV Vaccine's Protection and Response to Hepatitis B Booster Immunization in 5- to 7-Year-Old Children in the Kohgiloyeh and Boyerahmad Province, Iran. Hepatitis Monthly. 2010;10(1):17-21. PMid:22308120 PMCid:PMC3270339

Liop LG, Alcoverro AA, Mas PC, Benedito MAR, Juan CG. [Anti-HBs titres after a vaccination program in children and adolescents. Should a booster dose be given?]. An Esp Pediatr. 2001; 54(1):32-7. http://dx.doi.org/10.1016/S1695-4033(01)78646-8

Behjati M, Mirhoseini N, Ayatollahi J. [A Survey of immune status of primary school age children, 7 years post hepatitis B vaccination]. J Shaheed Sadoughi Univ Med Sci. 2002;10(3):3-7.

Sami SM, Salama II, Rabah TM, El Etreby LA, Abdel Halim NF, Hemeida SA. Hepatitis B long-termseroprotection and the response to a challenging dose among vaccinated children in Gharbeya Governorate. Medical Research Journal. 2013;12:81–87. http://dx.doi.org/10.1097/01.MJX.0000438131.28694.35

El-Sayed B, El-Guindi M, El-Shaarawy A, Salama EI, Sobhy GA. Long-term immunogenicity of hepatitis B vaccination in children. Zagazig J Occup Health Safety. 2009;2:17–28.

Wang L-Y, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBsnegative adolescents who had received primary vaccination 16 years ago. Vaccine. 2007; 7160– 7167. http://dx.doi.org/10.1016/j.vaccine.2007.07.022 PMid:17707557

Poorolaja lJ, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-termprotection provided by hepatitis B vaccine and need for booster dose: A meta-analysis. Vaccine. 2010;28:623–631. http://dx.doi.org/10.1016/j.vaccine.2009.10.068 PMid:19887132

Bernard D, Vladimir G, Nicole B, Philippe DW, Richard M, Gisele T, Gaston DS. Comparative Long Term Immunogenicity of Two Recombinant Hepatitis B Vaccines and the Effect of a Booster Dose Given After Five Years in a Low Endemicity Country. Pediatric Infectious Disease Journal. 2005;24(3):213-218. http://dx.doi.org/10.1097/01.inf.0000154329.00361.39

Lu CY1, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, Su IJ, Kuo HS, Huang LM, Chen DS, Lee CY Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis. 2008;197(10):1419-26. http://dx.doi.org/10.1086/587695 PMid:18444799

Saygun O, Eyigun CP, Avci IY, Kisa U, Pahsa A. Investigation (In Vivo and In Vitro) of Booster Dose Vaccine Requirement for Long-Term Protection against Hepatitis B Virus Infection Turk J Med Sci. 2009;39(2): 173-177.

Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet J-M, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infectious Diseases 2010. 2010; licensee Bio Med Central Ltd. http://www.biomedcentral.com/1471-2334/10/9.

Su FH, Cheng SH, Li CY, Chen JD, Hsiao CY, Chien CC, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine. 2007;25:8085–8090. http://dx.doi.org/10.1016/j.vaccine.2007.09.013 PMid:17920732

Wang LY, Lin HH. Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Journal of Hepatology. 2007;46:1018–1025. http://dx.doi.org/10.1016/j.jhep.2007.01.022 PMid:17399842



How to Cite

Sami SM, Salama II, Abdel-Latif GA, El Etreby LA, Metwally AI, Abd El haliem NF. Hepatitis B Seroprotection and the Response to a Challenging Dose among Vaccinated Children in Red Sea Governorate. Open Access Maced J Med Sci [Internet]. 2016 May 24 [cited 2023 Mar. 21];4(2):219-25. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2016.043



A - Basic Science

Most read articles by the same author(s)